Literature DB >> 32389832

Insights into pharmacological mechanisms of polydatin in targeting risk factors-mediated atherosclerosis.

Parvej Ahmad1, Sahir Sultan Alvi1, Danish Iqbal2, M Salman Khan3.   

Abstract

Polydatin (PD) is a monocrystalline metabolite from the underground parts of Polygonum cuspidatum Sieb. et Zucc., a member of the Polygonaceae family, which has been traditionally used in Asian countries as both foodstuffs and medicine. PD, also reckoned as pieceid, 3,4',5-trihydroxystilbene-3-β-D-glucoside, (E)-piceid, (E)-polydatin, and trans-polydatin. It possesses potent biological activities i.e. analgesic, anti-inflammatory, antidiabetic, anticancer, and anti-atherosclerotic properties. The initial part of this report specifically explains distinct sequential mechanisms underlying the initiation and development of atherosclerotic plaques and later part deals with the pharmacological efficacy of PD in the management of major cardiac event i.e. atherosclerotic cardiovascular diseases (ASCVD) via modulation of a set of molecular mechanisms i.e. antioxidant potential, lipid and lipoprotein metabolism including total cholesterol (TC) and low density lipoprotein (LDL) levels, β-hydroxy-β-methyl-glutaryl-CoA reductase (HMG-R) expression and functionality, SIRT signalling, LDL-receptor (LDL-R), LDL oxidation status (Ox-LDL), effects on endothelial cells (ECs), smooth muscle cells (SMCs), macrophage, foam cell formation and plaque stabilization, inflammatory signalling pathways and hypertension. In contrast, one of the major insight into the potential cardioprotective molecular mechanism is the PD-mediated targeting of proprotein convertase subtilisin/kexin type-9 (PCSK-9) and LDL-R pathway, both at transcriptional and protein functional level, which makes it a better alternative therapeutic medicinal candidate to treat hypercholesterolemia, especially for the patients facing inadequate lipid lowering with classical HMG-R inhibitors (statins) and statin intolerance. Finally, to sum up the whole, we concluded that PD may be promoted from alternative to mainstream medicine in targeting risk factors mediated ASCVD.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Cholesterol homeostasis; HMG-R; Inflammation; PCSK-9-LDL-R pathway; Polydatin

Year:  2020        PMID: 32389832     DOI: 10.1016/j.lfs.2020.117756

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  12 in total

1.  Synergistic Effect of Polydatin and Polygonatum sibiricum Polysaccharides in Combating Atherosclerosis via Suppressing TLR4-Mediated NF-κB Activation in ApoE-Deficient Mice.

Authors:  Genyi Ye; Yuhao Zhao; Junfeng Zhu; Zijian Zhang; Qiong Wang; Xu Jiang; Zhenxing Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-07       Impact factor: 2.650

2.  In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia.

Authors:  Suliman A Alsagaby; Danish Iqbal; Iqrar Ahmad; Harun Patel; Shabir Ahmad Mir; Yahya Awaji Madkhali; Atif Abdulwahab A Oyouni; Yousef M Hawsawi; Fahad A Alhumaydhi; Bader Alshehri; Wael Alturaiki; Bader Alanazi; Manzoor Ahmad Mir; Waleed Al Abdulmonem
Journal:  Sci Rep       Date:  2022-10-21       Impact factor: 4.996

3.  Soyasapogenol-B as a Potential Multitarget Therapeutic Agent for Neurodegenerative Disorders: Molecular Docking and Dynamics Study.

Authors:  Danish Iqbal; Syed Mohd Danish Rizvi; Md Tabish Rehman; M Salman Khan; Abdulaziz Bin Dukhyil; Mohamed F AlAjmi; Bader Mohammed Alshehri; Saeed Banawas; Qamar Zia; Mohammed Alsaweed; Yahya Madkhali; Suliman A Alsagaby; Wael Alturaiki
Journal:  Entropy (Basel)       Date:  2022-04-23       Impact factor: 2.738

4.  Protective Effects of Polydatin from Grapes and Reynoutria japonica Houtt. on Damaged Macrophages Treated with Acetaminophen.

Authors:  Can Liu; Wenyi Wang; Kaixin Zhang; Qiudi Liu; Tongyao Ma; Li Tan; Lanqing Ma
Journal:  Nutrients       Date:  2022-05-16       Impact factor: 6.706

5.  Exploring the Binding Pattern of Geraniol with Acetylcholinesterase through In Silico Docking, Molecular Dynamics Simulation, and In Vitro Enzyme Inhibition Kinetics Studies.

Authors:  Danish Iqbal; M Salman Khan; Mohd Waiz; Md Tabish Rehman; Mohammed Alaidarous; Azfar Jamal; Abdulaziz S Alothaim; Mohamed F AlAjmi; Bader Mohammed Alshehri; Saeed Banawas; Mohammed Alsaweed; Yahya Madkhali; Abdulrahman Algarni; Suliman A Alsagaby; Wael Alturaiki
Journal:  Cells       Date:  2021-12-14       Impact factor: 6.600

6.  Glycyrrhizic Acid Scavenges Reactive Carbonyl Species and Attenuates Glycation-Induced Multiple Protein Modification: An In Vitro and In Silico Study.

Authors:  Sahir Sultan Alvi; Rabia Nabi; Mohd Shahnawaz Khan; Firoz Akhter; Saheem Ahmad; M Salman Khan
Journal:  Oxid Med Cell Longev       Date:  2021-10-11       Impact factor: 6.543

Review 7.  Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management.

Authors:  Mohd Waiz; Sahir Sultan Alvi; M Salman Khan
Journal:  EXCLI J       Date:  2022-01-05       Impact factor: 4.068

8.  A descriptive study of commercial herbal dietary supplements used for dyslipidemia-Sales data and suspected adverse reactions.

Authors:  Olta Allkanjari; Francesca Menniti-Ippolito; Ilaria Ippoliti; Silvia Di Giacomo; Tito Piccioni; Annabella Vitalone
Journal:  Phytother Res       Date:  2022-05-07       Impact factor: 6.388

Review 9.  Impact of Phytochemicals on PPAR Receptors: Implications for Disease Treatments.

Authors:  Ayesheh Enayati; Mobina Ghojoghnejad; Basil D Roufogalis; Seyed Adel Maollem; Amirhossein Sahebkar
Journal:  PPAR Res       Date:  2022-08-31       Impact factor: 4.385

10.  Oxidized LDL Disrupts Metabolism and Inhibits Macrophage Survival by Activating a miR-9/Drp1/Mitochondrial Fission Signaling Pathway.

Authors:  Ting Xin; Chengzhi Lu; Jing Zhang; Jiaxin Wen; Shuangbin Yan; Chao Li; Feng Zhang; Jin Zhang
Journal:  Oxid Med Cell Longev       Date:  2020-11-01       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.